![](/img/cover-not-exists.png)
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
Perez, E. A., Dueck, A. C., McCullough, A. E., Reinholz, M. M., Tenner, K. S., Davidson, N. E., Gralow, J., Harris, L. N., Kutteh, L. A., Hillman, D. W., Jenkins, R. B., Chen, B.Volume:
104
Language:
english
Journal:
JNCI Journal of the National Cancer Institute
DOI:
10.1093/jnci/djr490
Date:
January, 2012
File:
PDF, 245 KB
english, 2012